

**CBE ID**

0636

**Title**

Atherosclerotic Disease and LDL Greater than 100 - Use of Lipid Lowering Agent

**Project**

National Voluntary Consensus Standards For Clinically Enriched Administrative Data

**Endorsement Status**

Endorsement Removed

**Is Under Review**

No

**Previous Endorsement Cycle**

Full Year 2009

**Removal Date**

Wed, 12/11/2013 - 19:00

**Initial Endorsement**

Thu, 12/03/2009 - 19:00

**Steward**

ActiveHealth Management

**1.0 New or Maintenance**

Maintenance

**1.1 Measure Structure**

Single Measure

**1.3 Electronic Clinical Quality Measure (eCQM)**

No

**1.6 Measure Description**

The percentage of patients aged 18 and older with a diagnosis of atherosclerotic disease whose most recent LDL-C value is greater than 100 mg/dL and who are taking a lipid lowering agent

**1.7 Measure Type**

Process

**1.8 Level of Analysis**

Clinician: Group/Practice, Clinician: Individual, Facility, Health Plan, Integrated Delivery System,

---

Other, Population: Community, County or City, Population: Regional and State

## **1.9 Care Setting**

Home Care, Outpatient Services

## **1.14 Numerator**

Patients with a current fill for a lipid lowering agent

## **1.15 Denominator**

Patients with a diagnosis of atherosclerotic disease and whose most recent LDL-C is greater than 100 mg/dL.

## **1.20 Types of Data Sources**

Claims Data, Electronic Health Data, Electronic Health Records: Electronic Health Records, Instrument-Based Data, Other

## **6.1.2 Current or Planned Use(s)**

Public Reporting, Quality Improvement (Internal to the specific organization)

## **6.1.3 Current Use(s)**

Public Reporting, Quality Improvement (Internal to the specific organization)

## **Exclusions**

General exclusions:

1. Evidence of metastatic disease or active treatment of malignancy (chemotherapy or radiation therapy) in the last 6 months
2. Patients who have been in a skilled nursing facility in the last 3 months
3. Patients who are terminally ill or in Hospice
4. Patient or provider feedback indicating allergy, intolerance or other contraindication to lipid lowering therapy anytime in the past

## **Planned Use**

Public Reporting, Quality Improvement (Internal to the specific organization)

## **Risk Adjustment**

No risk adjustment or risk stratification

## **Steward Organization**

ActiveHealth Management

## **Steward POC email**

mvemireddy@activehealth.net